Back to top
more

Progyny (PGNY)

(Real Time Quote from BATS)

$13.70 USD

13.70
1,326,519

-0.28 (-2.00%)

Updated Nov 15, 2024 03:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (141 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

ELV vs. PGNY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ELV vs. PGNY: Which Stock Is the Better Value Option?

ELV or PGNY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ELV vs. PGNY: Which Stock Is the Better Value Option?

Wall Street Analysts See a 64% Upside in Progyny (PGNY): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 63.5% upside potential for Progyny (PGNY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Progyny (PGNY) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Progyny (PGNY) delivered earnings and revenue surprises of 160% and 5.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ELV or PGNY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ELV vs. PGNY: Which Stock Is the Better Value Option?

Progyny (PGNY) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AMN or PGNY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMN vs. PGNY: Which Stock Is the Better Value Option?

MODV vs. PGNY: Which Stock Is the Better Value Option?

by Zacks Equity Research

MODV vs. PGNY: Which Stock Is the Better Value Option?

Does Progyny (PGNY) Have the Potential to Rally 64% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 63.5% in Progyny (PGNY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

MODV vs. PGNY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

MODV vs. PGNY: Which Stock Is the Better Value Option?

Can Progyny (PGNY) Climb 47% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 46.6% in Progyny (PGNY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

AMN vs. PGNY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

AMN vs. PGNY: Which Stock Is the Better Value Option?

Progyny (PGNY) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Progyny (PGNY) delivered earnings and revenue surprises of 350% and 2.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Molina Healthcare (MOH) to Buy My Choice Wisconsin for $150M

by Zacks Equity Research

Molina Healthcare (MOH) expects the buyout to complement its existing Medicaid business in Wisconsin.

Encompass Health (EHC) to Build New Rehab Unit in Missouri

by Zacks Equity Research

Encompass Health (EHC) and BJC HealthCare's new rehabilitation hospital is expected to come online in 2024.

Progyny (PGNY) Upgraded to Buy: Here's Why

by Zacks Equity Research

Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Will Mednax's (MD) New Name Pediatrix Medical be Beneficial?

by Zacks Equity Research

Mednax's (MD) name change is expected to take effect following the closing bell on Jul 1, 2022.

    UnitedHealth (UNH) Unit Eyes $1.5B EMIS Acquisition in UK

    by Zacks Equity Research

    UnitedHealth's (UNH) Optum business operates in the United Kingdom for two decades and the acquisition is expected to boost its footprint in the country.

    HCA Healthcare (HCA) Scraps Utah Buyout Post FTC's Roadblock

    by Zacks Equity Research

    HCA Healthcare's (HCA) aborted acquisition follows another abandoned buyout plan involving RWJBarnabas Health and Saint Peter's Healthcare System.

    Centene (CNC) Raises 2022 Guidance, Ups Share Buyback Fund

    by Zacks Equity Research

    Currently, Centene (CNC) has $3.6 billion remaining under its share buyback program.

    Cigna (CI) Signs $3.5B Accelerated Share Buyback Agreements

    by Zacks Equity Research

    Cigna (CI) intends to buy back at least $7 billion worth of its stocks this year alone.

    Encompass Health (EHC) Forms JV With NCH Healthcare in Naples

    by Zacks Equity Research

    The NCH Healthcare System's board grants approval to invest in the joint venture with Encompass Health (EHC).

    Encompass Health (EHC) Plans to Distribute Enhabit Shares

    by Zacks Equity Research

    Every Encompass Health (EHC) shareholder will receive one Enhabit common share for every two EHC common shares held.

    Should You Hold On to Teladoc Health (TDOC) Stock for Now?

    by Zacks Equity Research

    Teladoc Health's (TDOC) cash flows will likely gain from the growing number of visits and memberships.